Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Stocks hover near record high, oil skids on demand outlook

11/27/2020 | 12:58am EST

* Asian stock markets: https://tmsnrt.rs/2zpUAr4

* Highly-anticipated vaccine facing more scrutiny

* Equity markets pull back from record highs

* Oil hit by concerns about oversupply

* U.S. financial markets closed Thursday for Thanksgiving

TOKYO, Nov 27 (Reuters) - Asian shares stalled near record highs on Friday as investors weighed renewed doubts about a highly-anticipated coronavirus vaccine against hopes that some of the region's economies will recovery quicker than their Western peers.

MSCI's broadest index of Asia-Pacific shares outside Japan dipped 0.04% but remained with striking distance of a life-time peak touched this week.

Australian shares ended down 0.53%. Treasury Wine Estates Ltd tumbled by 11.25% after China slapped tariffs on Australian wine, which is likely to worsen a diplomatic row between Beijing and Canberra.

Japan's Nikkei rose 0.33% in choppy trade.

Shares in China rose 0.13% after data showed Chinese industrial profits surged at the fastest pace since early 2017. South Korean stocks also rose 0.27%.

U.S. S&P 500 e-mini stock futures fell 0.09%. U.S. financial markets were closed on Thursday for the Thanksgiving holiday and will trade on a partial schedule later on Friday.

Euro Stoxx 50 futures were down 0.26%, German DAX futures fell 0.24%, and FTSE futures were down 0.22%, suggesting a soft start to the European session.

U.S. oil prices extended their declines from a seven-month high due to signs of oversupply.

British drugmaker AstraZeneca's coronavirus drug was touted as a "vaccine for the world" due to its inexpensive cost, but the efficacy of the vaccine is now facing more intense scrutiny, which experts say could delay its approval.

Several scientists have raised doubts about the robustness of results showing the shot was 90% effective in a sub-group of trial participants who, by error initially, received a half dose followed by a full dose.

"With global case numbers having now topped 60 million... there is certainly some rough terrain ahead for the global recovery, and that can create economic scarring," analysts at ANZ Bank wrote in a memo.

MSCI's broadest gauge of world stocks was up 0.08% on Friday, sitting just below a record high reached in the previous session.

Concerns about the distribution of a coronavirus vaccine have placed renewed focus on the current state of the pandemic, which looks grim for many places.

U.S. hospitalizations for COVID-19 are at a record and experts warn that Thanksgiving gatherings could lead to further infections and deaths.

More than 20 million people across England will be forced to live under the toughest restrictions even after a national lockdown ends on Dec. 2. Partial lockdowns in some European countries have also raised concern about economic growth.

The European Central Bank's chief economist highlighted these concerns in dovish comments on Thursday, which pushed European bond yields lower.

The euro, which last bought $1.1924, showed little reaction because currency traders have largely priced in expectations for additional ECB easing next month.

The dollar index fell toward its lowest in more than two months.

The yield on benchmark 10-year Treasury notes fell to 0.8586% as some investors sought the safety of holding government debt.

U.S. crude dipped 1.82% to $44.88 a barrel. Brent crude fell 0.17% to $47.72 per barrel.

Fuel demand is falling due to renewed coronavirus lockdowns, but some oil producers are not complying with agreed production cuts, which raises concerns about oversupply.

Bitcoin, the world's biggest cryptocurrency, edged up to $17,256 on Thursday, but it tumbled by 8.4% in the previous session after failing to take out its record high of $19,666.

The cryptocurrency showed little reaction to a report in the Financial Times that Facebook will launch its own Libra digital currency in limited format next year.

Bitcoin has rallied around 140% this year, fuelled by demand for riskier assets.

(Reporting by Stanley White; editing by Richard Pullin, Lincoln Feast and Kim Coghill)

© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC -1.00% 7645 Delayed Quote.5.43%
BITCOIN - EURO -3.00% 28920.25 Real-time Quote.26.41%
DAX 0.77% 13921.37 Delayed Quote.0.70%
DJ INDUSTRIAL 0.83% 31194.05 Delayed Quote.0.68%
EURO / US DOLLAR (EUR/USD) -0.29% 1.2099 Delayed Quote.-0.61%
EURO STOXX 50 0.80% 3624.04 Delayed Quote.1.20%
FACEBOOK INC 2.85% 268.48 Delayed Quote.-4.42%
LONDON BRENT OIL -0.21% 55.84 Delayed Quote.5.90%
NASDAQ 100 2.43% 13314.979679 Delayed Quote.0.84%
NASDAQ COMP. 2.16% 13470.798149 Delayed Quote.0.86%
NIKKEI 225 -0.38% 28523.26 Real-time Quote.4.33%
S&P 500 1.48% 3855.44 Delayed Quote.1.14%
TREASURY WINE ESTATES LIMITED -1.18% 9.24 End-of-day quote.-1.70%
WTI -0.20% 53.089 Delayed Quote.8.53%
All news about ASTRAZENECA PLC
03:38pWHO plans slew of COVID-19 vaccine approvals for global rollout
11:56aThree COVID-19 vaccines under final review for emergency use - WHO
11:43aGlass maker Schott predicts enough vials to go around for COVID-19 vaccines
10:26aWHO plans slew of COVID-19 vaccine approvals for global rollout - document
09:03aASTRAZENECA : India, 'pharmacy of the world', starts COVID vaccine shipments to ..
06:01aASTRAZENECA : Receives a Buy rating from Credit Suisse
05:59aASTRAZENECA : Thai opposition figure accused of insulting king for criticizing v..
05:45aASTRAZENECA : Oxford-AstraZeneca's Covid-19 Vaccine Helps U.K. Lead Race to Reac..
05:31aPfizer vaccine appears effective against coronavirus variant found in Britain..
04:48aAstraZeneca Secures Conditional Approval for Enhertu as Monotherapy for Breas..
More news
Financials (USD)
Sales 2020 26 394 M - -
Net income 2020 2 967 M - -
Net Debt 2020 13 227 M - -
P/E ratio 2020 41,3x
Yield 2020 2,67%
Capitalization 137 B 137 B -
EV / Sales 2020 5,69x
EV / Sales 2021 4,90x
Nbr of Employees 70 600
Free-Float 95,7%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 25
Average target price 125,95 $
Last Close Price 105,34 $
Spread / Highest target 48,1%
Spread / Average Target 19,6%
Spread / Lowest Target -20,2%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON3.43%428 525
ROCHE HOLDING AG2.98%307 190
NOVARTIS AG2.24%218 823
MERCK & CO., INC.1.70%210 474
PFIZER INC.-0.22%204 160